Modern oral contraceptives and dysmenorrhoea

Area of Science:

• Gynecology
• Pharmacology
• Women's Health

Background:

• Primary dysmenorrhea significantly impacts women's quality of life.
• Existing treatments, such as triphasic oral contraceptives (OCs), may not provide sufficient relief for all patients.

Purpose of the Study:

• To evaluate the efficacy of a modern, low-dose monophasic OC as an alternative treatment for women with primary dysmenorrhea.
• To compare the effectiveness of a monophasic OC against previous treatments in a specific patient group.

Main Methods:

• A cohort of women with primary dysmenorrhea, inadequately managed by triphasic OCs, were offered a monophasic OC.
• The monophasic OC contained 30 micrograms of ethinylestradiol and 150 micrograms of desogestrel.
• Treatment continuation rates were assessed to determine patient acceptance and perceived efficacy.

Main Results:

• The monophasic oral contraceptive (OC) proved to be a superior treatment option for women with primary dysmenorrhea who had insufficient relief from triphasic OCs.
• A high continuation rate (19 out of 23 women) indicates significant patient satisfaction and therapeutic benefit.

Conclusions:

• A low-dose monophasic oral contraceptive (OC) containing ethinylestradiol and desogestrel is an effective and well-tolerated alternative for managing primary dysmenorrhea.
• This monophasic OC formulation may be considered a suitable first-line treatment option for women experiencing inadequate symptom control with other oral contraceptives.